Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Eduvest - Journal of Universal Studies
I Gusti Sri Agung Jaya Kusumadewi
Universitas Warmadewa
Aerospace Engineering Computer Science & IT Health Professions Neuroscience Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Comparison Between Efficacy Outcomes Of Covalent Versus Non Covalent Bruton Tyrosine Kinase (Btk) Inhibitor Treatments For Double-Exposed Chronic Lyhmpocitic Leukemia And Small Lymphocitic Lymphoma Patients: A Systematic Review Ogek Dwi Shavitri; Bgs Gde Ariesta Darmahendra; I Gusti Sri Agung Jaya Kusumadewi
Eduvest - Journal of Universal Studies Vol. 6 No. 7 (2026): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v6i7.53189

Abstract

Background: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B-cell malignancy. Covalent Bruton tyrosine kinase inhibitors (cBTKis) such as ibrutinib, acalabrutinib, and zanubrutinib have improved outcomes but are limited by resistance mutations at the BTK C481 site. Non-covalent BTK inhibitors (ncBTKis) like pirtobrutinib were developed to overcome this resistance. This review compares clinical outcomes between covalent and non-covalent BTK inhibitors in CLL/SLL. Methods: A systematic search of MEDLINE, CENTRAL, and EMBASE identified studies within the last 10 years evaluating cBTKis and ncBTKis in CLL/SLL. Eligible studies reported efficacy outcomes, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Quality was assessed using the Newcastle–Ottawa Scale.Results: Four studies involving 137 patients met inclusion criteria. Among ncBTKis, pirtobrutinib showed 70% PR and 11% SD, while nemtabrutinib showed 25% PR without CR. Covalent BTKi combinations achieved higher CR rates: ibrutinib + venetoclax (CR 55%, PR 45%) and acalabrutinib + obinutuzumab (CR 50%). PD rates were inconsistently reported.Conclusion: Covalent BTKi-based combinations produced deeper responses than ncBTKi monotherapy, likely due to synergistic mechanisms and earlier treatment lines. Non-covalent BTKis remain valuable for patients with cBTKi resistance but achieve limited CRs when used alone. Future trials combining ncBTKis with BCL-2 inhibitors or anti-CD20 antibodies may enhance remission depth and durability in refractory CLL/SLL.
Cardiovascular Outcomes of Tirzepatide Compared with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) and Insulin in Patients with Type-2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials I Gusti Sri Agung Jaya Kusumadewi; Pauliana Pauliana; Wira Gotera
Eduvest - Journal of Universal Studies Vol. 6 No. 9 (2026): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v6i9.53381

Abstract

Cardiovascular disease remains a major cause of morbidity and mortality among patients with type 2 diabetes mellitus, highlighting the need for antidiabetic therapies that provide metabolic benefits without increasing cardiovascular risk. This study aimed to evaluate the cardiovascular outcomes of tirzepatide compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), insulin therapy, and placebo in adults with type 2 diabetes mellitus. A systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. PubMed, Scopus, CENTRAL, and ScienceDirect databases were searched from inception to April 2026. Seven randomized controlled trials involving 21,108 participants met the eligibility criteria. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using the Mantel–Haenszel method, and subgroup analyses were performed according to comparator class. Tirzepatide did not significantly alter the risk of myocardial infarction compared with pooled comparators (RR 1.97; 95% CI 0.52–7.43; p = 0.31) or stroke (RR 2.47; 95% CI 0.45–13.52; p = 0.30). The risk of all-cause mortality was also comparable between groups (RR 1.05; 95% CI 0.38–2.89; p = 0.92). Comparator-based subgroup analyses yielded similarly nonsignificant results. In conclusion, tirzepatide demonstrated a cardiovascular safety profile comparable to GLP-1 receptor agonists, insulin therapy, and placebo; however, additional long-term studies are required to determine whether it provides superior cardiovascular benefits.
Co-Authors Bgs Gde Ariesta Darmahendra Ogek Dwi Shavitri Pauliana Pauliana Wira Gotera